Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Xenon Pharmaceuticals Inc (XENE)

Pharmaceutical Preparations

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

200 - 3650 GILMORE WAY
BURNABY, A1

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/05/2014

Market Cap

2,882,839,225

Shares Outstanding

73,890,000

Weighted SO

75,275,868

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

NUVL --.--%

DICE --.--%

ACLX --.--%

PCVX --.--%

VRDN --.--%

CRNX --.--%

INBX --.--%

MRUS --.--%

LYEL --.--%

Beta

1.2650

Last Div

0.0000

Range

27.985-50.99

Chg

-0.2000

Avg Vol

430704

Mkt Cap

2882839225

Exch

NASDAQ

Country

CA

Phone

16044843300

DCF Diff

35.9908

DCF

2.0592

Div Yield

0.0000

P/S

535.8437

EV Multiple

-11.7076

P/FV

3.5014

Div Yield %

0.0000

P/E

-14.8467

PEG

0.4656

Payout

0.0000

Current Ratio

23.2728

Quick Ratio

23.2728

Cash Ratio

4.3706

DSO

57.8708

DIO

0.0000

Op Cycle

57.8708

DPO

902.0999

CCC

-844.2291

Gross Margin

0.2857

Op Margin

-44.1494

Pretax Margin

-37.0526

Net Margin

-37.0000

Eff Tax Rate

0.0014

ROA

-0.2252

ROE

-0.2416

ROCE

-0.2785

NI/EBT

0.9986

EBT/EBIT

0.8393

EBIT/Rev

-44.1494

Debt Ratio

0.0015

D/E

0.0016

LT Debt/Cap

0.0000

Total Debt/Cap

0.0016

Int Coverage

-31.1957

CF/Debt

-111.6972

Equity Multi

1.0473

Rec Turnover

6.3072

Pay Turnover

0.4046

Inv Turnover

0.0000

FA Turnover

0.2875

Asset Turnover

0.0061

OCF/Share

-1.9472

FCF/Share

-1.9844

Cash/Share

9.2896

OCF/Sales

-28.1112

FCF/OCF

1.0191

CF Coverage

-111.6972

ST Coverage

-111.6972

CapEx Coverage

-52.2622

Div&CapEx Cov

-52.2622

P/BV

3.5014

P/B

3.5014

P/S

535.8437

P/E

-14.8467

P/FCF

-18.7037

P/OCF

-19.5413

P/CF

-19.5413

PEG

0.4656

P/S

535.8437

EV Multiple

-11.7076

P/FV

3.5014

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 03, 08:30 Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Benzinga Dec 08, 11:00 4 Analysts Have This to Say About Xenon Pharmaceuticals GlobeNewswire Inc. Dec 02, 12:01 Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) GlobeNewswire Inc. Dec 02, 12:01 Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) GlobeNewswire Inc. Dec 02, 12:01 Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) GlobeNewswire Inc. Dec 02, 12:01 Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) GlobeNewswire Inc. Nov 29, 22:51 Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering GlobeNewswire Inc. Nov 29, 22:51 Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering GlobeNewswire Inc. Nov 29, 22:51 Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering GlobeNewswire Inc. Nov 29, 22:51 Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering Benzinga Nov 27, 14:10 Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst Benzinga Nov 27, 14:10 Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst Benzinga Nov 27, 13:41 Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session Benzinga Nov 10, 13:43 Why Is Neurocrine Biosciences Stock Trading Lower Today?

Revenue Product Segmentation